References for this Review were identified through searches of PubMed for articles published from Jul, 1976, to Oct, 2012 by use of the terms “sepsis”, “immunosuppression”, “immunoparalysis”, and “immunotherapy”. Only papers published in English were used.
ReviewImmunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Introduction
The failure of several high-profile clinical trials in sepsis has led researchers to state that sepsis studies need new direction.1, 2, 3, 4, 5, 6 Experts have discussed important reasons for the failures of new investigative drugs and highlighted problems in design and conduct of sepsis trials.1, 2, 3, 4, 5, 6 However, there might also be inadequate understanding of key pathophysiological mechanisms that operate in sepsis. Post-mortem studies of patients who died of sepsis have provided important insights into why septic patients die, and highlighted key immunological defects that impair host immunity.7, 8 Several small phase 2 clinical trials of immune-enhancing drugs have shown benefit, thereby substantiating the concept that immunosuppression has a central role.9, 10 Findings from studies of clinically relevant animal models of sepsis that mimic the protracted nature of the disease also support the premise that boosting immunity improves survival.11 Sepsis and cancer share many immunological defects, and therefore the recent successes of several immunomodulatory drugs in cancer provide hope for and insight into potential immunostimulatory therapies in sepsis.12, 13, 14
Section snippets
Sepsis as a cytokine storm
Patients with sepsis often present with high spiking fevers, shock, and respiratory failure. Partly because of this striking presentation, the prevailing theory of sepsis for many years was that it represented an uncontrolled inflammatory response.15 The discovery that various potent cytokines, including tumour necrosis factor (TNF) and interleukin 1, are at increased concentrations in patients with sepsis, and when injected into animals reproduced many clinical and laboratory features of
Why do patients with sepsis die?
Whereas some patients rapidly succumb to massive proinflammatory cytokine-driven inflammation as occurs, for example, in toxic shock syndrome and meningococcaemia, improved treatment algorithms have resulted in most patients surviving the early hyperinflammatory phase of sepsis and entering a more protracted phase.22, 23 More than 70% of deaths in sepsis occur after the first 3 days of the disorder, with many deaths occurring weeks later. In a post-mortem study, Torgersen and colleagues7
Sepsis as an immunosuppressive disorder
Although both proinflammatory and anti-inflammatory processes begin promptly after sepsis initiation, in general there is predominance of an initial hyperinflammatory phase, the scale of which is determined by many factors including pathogen virulence, bacterial load, host genetic factors, age, and host comorbidities. For example, a previously healthy young adult who develops meningococcaemia will likely have a profound hyperinflammatory cytokine-storm-mediated response, that causes shock, high
Post-mortem and gene-expression clinical studies
Results from an important post-mortem study showed that sepsis-induced immunosuppression occurred in major organs, not just within circulating leucocytes.8 Rapid post-mortem spleen and lung harvest was done 30–180 min after death in 40 patients with sepsis. Cytokine secretion studies and immunophenotyping of cell-surface receptor or ligand expression profiles were done to discover potential mechanisms of immunosuppression. A striking finding was that lipopolysaccharide-stimulated splenocytes
New approaches: immunomodulatory therapy
Sepsis can be thought of as a race to the death between the invading microbes and the host immune response, and the pathogens seek an advantage by incapacitating various aspects of host immunity. Most previous sepsis drug trials used compounds that blocked the host response to pathogens or limited inflammation. There is likely a role for drugs that block inflammatory cytokines in sepsis; however, such agents should be shortacting, applied early in sepsis, and used only in patients who have
Conclusion
In the future, immunomodulatory therapies in sepsis will be personalised on the basis of particular laboratory and clinical findings, or both—eg, the use of GM-CSF dependent on monocyte HLA-DR expression (table).1, 9, 10 Similarly, flow cytometry quantitation of circulating immune cell expression of PD-1/PD-L1 or rapid whole-blood stimulation assays of cytokine secretion could be used to guide immunotherapy. Finally, patients with infections caused by opportunistic pathogens (eg, Enterococcus
Search strategy and selection criteria
References (84)
- et al.
Sepsis studies need new direction
Lancet Infect Dis
(2012) The rise and fall of drotrecogin alfa (activated)
Lancet Infect Dis
(2012)- et al.
Anti-inflammatory cytokine profile and mortality in febrile patients
Lancet
(1998) - et al.
Downregulation of proinflammatory cytokine release in whole blood from septic patients
Blood
(1995) - et al.
Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production
Surgery
(2000) - et al.
Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria
Chest
(2008) - et al.
Interleukin 7, maestro of the immune system
Semin Immunol
(2012) - et al.
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology
Cell
(2011) - et al.
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
Blood
(2011) - et al.
Septic shock: evaluating another failed treatment
N Engl J Med
(2012)
After Xigris, researchers look to new targets to combat sepsis
Nat Med
Trial failure prompts soul-searching for critical-care specialists
Nat Med
The search for effective therapy for sepsis: back to the drawing board?
JAMA
Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis
Anesth Analg
Immunosuppression in patients who die of sepsis and multiple organ failure
JAMA
Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial
Am J Respir Crit Care Med
Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome
Intensive Care Med
IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis
J Immunol
Improved survival with ipilimumab in patients with metastatic melanoma
N Engl J Med
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
N Engl J Med
Twelve immunotherapy drugs that could cure cancers
Immunol Rev
The pathophysiology and treatment of sepsis
N Engl J Med
Dysregulation of in vitro cytokine production by monocytes during sepsis
J Clin Invest
Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis
Shock
Downregulation of CD40 ligand response in monocytes from sepsis patients
Clin Vaccine Immunol
Bundled care for septic shock: an analysis of clinical trials
Crit Care Med
Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony
Mol Med
Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction
Crit Care Med
Mechanisms of organ dysfunction in critical illness: report from a round table conference held in Brussels
Intensive Care Med
Mechanisms of sepsis-induced organ dysfunction
Crit Care Med
Mortality due to septic shock following early, appropriate antibiotic therapy: can we do better?
Crit Care Med
The late phase of sepsis is characterized by an increased microbiological burden and death rate
Crit Care
The effect of age on the development and outcome of adult sepsis
Crit Care Med
Immunosenescence and challenges of vaccination against influenza in the aging population
Aging Dis
Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma
Ann Surg
Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans
J Immunol
Depletion of dendritic cells, but not macrophages, in patients with sepsis
J Immunol
Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure
J Immunol
Spleen depletion in neonatal sepsis and chorioamnionitis
Am J Clin Pathol
Regulatory T cell populations in sepsis and trauma
J Leukoc Biol
Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients
Intensive Care Med
Increased proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells during the early-stage sepsis in ICU patients
J Microbiol Immunol Infect
Cited by (1091)
The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells
2024, Chinese Journal of Traumatology - English EditionCombating bacterial infections with host defense peptides: Shifting focus from bacteria to host immunity
2024, Drug Resistance UpdatesInflammatory biomarkers to predict the prognosis of acute bacterial and viral infections
2023, Journal of Critical Care